Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Aimee
Aimee Cossins, Oxfordshire GB
| Patent application number | Description | Published |
|---|---|---|
| 20110177056 | NON-CYTOTOXIC FUSION PROTEINS COMPRISING EGF MUTEINS - The present invention relates to fusion proteins comprising a non-cytotoxic protease and a EGF mutein ligand. The EGF mutein provides improved EGF receptor activation for the claimed fusion proteins. Also provided is the use of said polypeptides as therapeutics for suppressing mucus hypersecretion, inflammation, endocrine neoplasia and/or neuroendocrine disorders, neuroendocrine tumours, for suppressing cancers such as colorectal cancer, prostate cancer, breast cancer, and lung cancer. | 07-21-2011 |
Aimee Dessinges, Ruiel-Malmaison FR
| Patent application number | Description | Published |
|---|---|---|
| 20090075982 | Piperazine compounds - A compound selected from those of formula (I): | 03-19-2009 |
| 20090076030 | Piperazine compounds - A compound selected from those of formula (I): | 03-19-2009 |
Aimee Parow, Phoenix, AZ US
| Patent application number | Description | Published |
|---|---|---|
| 20120022315 | Magnetic Field Treatment Techniques - The invention involves enhancing brain function by stimulating the brain using magnetic fields. Applications of the new methods include improving the condition of individuals with cognitive disorders, such as depression, and studying the effects of neural stimulation using induced electric fields. These techniques can avoid deleterious effects of psychotropic pharmaceutical treatments, and provide a relatively safe, comfortable, inexpensive means of direct cranial stimulation. | 01-26-2012 |
Aimee Powelka, Framingham, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090221676 | GLUCOSE-TRANSPORT RELATED GENES, POLYPEPTIDES, AND METHODS OF USE THEREOF - Methods and compositions for modulating glucose transport are provided herein. | 09-03-2009 |
| 20100098638 | RIP140 Regulation of Diabetes - Inhibition of RIP140 increases glucose transport. Compounds that inhibit RIP140 expression or activity are useful for treating disorders associated with aberrant glucose transport (e.g., diabetes), treating obesity, increasing metabolism (e.g., fatty acid metabolism), and increasing brown fat. | 04-22-2010 |
Aimee Tharaldson, Woodbury, MN US
| Patent application number | Description | Published |
|---|---|---|
| 20090192807 | Identification of specialty drugs - Methods for determining whether a drug is a specialty drug, methods for creating tools to be used in making the determination, and the tools themselves are disclosed. The overall value of a drug depends on the drug's attribute values with respect to each of a set of drug attributes (concerning, e.g., the drug's route of administration, targeted disease, possible adverse reactions, risk of toxicity, cost, need for patient compliance with the treatment regime, and handling, preparation, and/or storage requirements. If the overall value or its partial overall values meet certain criteria, the drug is deemed to be a specialty drug. | 07-30-2009 |
| 20110307271 | IDENTIFICATION OF SPECIALTY DRUGS - Methods for determining whether a drug is a specialty drug, methods for creating tools to be used in making the determination, and the tools themselves are disclosed. The overall value of a drug depends on the drug's attribute values with respect to each of a set of drug attributes (concerning, e.g., the drug's route of administration, targeted disease, possible adverse reactions, risk of toxicity, cost, need for patient compliance with the treatment regime, and handling, preparation, and/or storage requirements. If the overall value or its partial overall values meet certain criteria, the drug is deemed to be a specialty drug. | 12-15-2011 |
Aimee Willmeno, Eureka, MO US
| Patent application number | Description | Published |
|---|---|---|
| 20110153478 | Device and Method for Settlement Optimization - A settlement device for optimizing a transaction includes an input module, a processor, and an output module. The input module receives transaction data of the transaction. The processor determines an optimal location to process the transaction as a function of predetermined rules. The output module transmits the transaction data to the optimal location. | 06-23-2011 |